Iovance Biotherapeutics ((IOVA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iovance Biotherapeutics is conducting a Phase 1 clinical study titled A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors. The study aims to assess the safety and effectiveness of TIL therapy in young patients with solid tumors that have relapsed or are unresponsive to standard treatments.
The intervention involves using a biological treatment, LN-145/LN-144, where tumor samples are taken from patients and cultured to expand tumor-infiltrating lymphocytes. This approach is intended to enhance the body’s immune response against cancer.
The study is interventional, non-randomized, and follows a parallel assignment model with no masking. Its primary purpose is treatment, focusing on evaluating the TIL regimen’s safety and antitumor activity.
The study began on July 17, 2024, with an estimated primary completion date of two years post-treatment for each participant. The latest update was submitted on June 26, 2025, indicating ongoing recruitment.
This study update could positively influence Iovance Biotherapeutics’ stock performance, as successful results may enhance investor confidence in the company’s innovative cancer therapies. It also positions Iovance competitively within the biopharmaceutical industry, where advancements in immunotherapy are highly valued.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.